Clinical Trial: NCT06400472
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Status:
RECRUITINGPhase:
Phase 1| Lead Sponsor: | Eli Lilly and Company |
| Information Provided By: | Eli Lilly and Company |
| Last Update Posted: | 2026-11-04 |
Study Overview
Brief Summary
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion). The study will last up to approximately 5 years.
Official Title
A First-in-Human, Phase 1/2 Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Sofetabart Mipitecan (LY4170156), an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
Conditions
Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms
Intervention / Treatment
- Drug: Sofe-M
- Drug: bevacizumab
- Drug: carboplatin
- Drug: Itraconazole
- Drug: pembrolizumab
Other Study ID Numbers
- 18863
- 2024-511238-11-00
- J5E-OX-JZXA
- LOXO-FRA-24001
Start Date (Actual)
2024-05-20
Primary Completion Date (Estimated)
2029-06
Study Completion Date (Estimated)
2029-06
Enrollment (Estimated)
575
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Eli Lilly and Company |
| Information Provided By: | Eli Lilly and Company |
| Last Update Posted: | 2026-11-04 |
Study Overview
Brief Summary
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion). The study will last up to approximately 5 years.
Official Title
A First-in-Human, Phase 1/2 Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Sofetabart Mipitecan (LY4170156), an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
Conditions
Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms
Intervention / Treatment
- Drug: Sofe-M
- Drug: bevacizumab
- Drug: carboplatin
- Drug: Itraconazole
- Drug: pembrolizumab
Other Study ID Numbers
- 18863
- 2024-511238-11-00
- J5E-OX-JZXA
- LOXO-FRA-24001
Start Date (Actual)
2024-05-20
Primary Completion Date (Estimated)
2029-06
Study Completion Date (Estimated)
2029-06
Enrollment (Estimated)
575
Study Type
Interventional
Phase
Phase 1